High fetal hemoglobin (HbF, a 2 g 2 ) levels ameliorate the clinical manifestations of sickle cell disease and b thalassemia. The mechanisms that repress HbF expression and silence g-globin genes in adults are incompletely characterized and only a single HbF inducer, hydroxyurea, is approved for treatment, and only in patients with sickle cell disease. We identified SIRT1, a protein deacetylase, as a new inducer of g-globin. SIRT1 knockdown decreased, while SIRT1 ectopic expression upregu- 
| I N TR ODU C TI ON
Sickle cell anemia and b thalassemia, the b hemoglobinopathies, are caused by mutations that affect, respectively, the structure and expression of the adult hemoglobin b-globin chain (HbA; a 2 b 2) . 1 Fetal hemoglobin (HbF; a 2 g 2 ) is the major modulator of the phenotype of both diseases. 2 In adults, HbF is replaced by HbA and HbF is normally constitutes less than 1% of total hemoglobin due to the silencing of the g-globin genes (HBG). 3 Reactivation of HBG expression in adults is a prime strategy for both cell-based and pharmacologic treatment of the b hemoglobinopathies. 4, 5 Hydroxyurea, a HbF inducer, was the first approved drug for treating sickle cell disease, but the HbF response to this treatment is variable and suboptimal, and additional agents would be useful. , and b-globin (HBB) genes. 9 The LCR physically interacts with the promoters of its target genes to form chromatin loops and regulate gene expression. 10, 11 Transcription factors recruit corepressors and co-activators to form multiprotein transcription complexes to bind the LCR or target gene promoters and silence or activate HBG transcription. [12] [13] [14] Overall, HBG transcriptional regulation is a collaborative action of cis-acting elements with transcription factors along with co-activators and co-repressors. [14] [15] [16] [17] [18] However, the complex mechanism of HBG expression and silencing is not totally understood.
SIRT1 encodes a nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase that removes acetyl groups from many nonhistone and histone proteins, 19 and therefore is involved in a broad range of physiological functions, including control of gene expression, cell growth, DNA repair, oxidative stress, metabolism and aging. 20, 21 SIRT1
plays a critical role in transcriptional regulation through several different mechanisms. 22 It interacts with and deacetylates a broad range of transcription factors and co-regulators to control transcription complex formation, thereby regulating gene transcription both positively and negatively. 21, [23] [24] [25] SIRT1 can directly deacetylate histones and promote alterations in the methylation of histones and DNA, leading to the repression of gene transcription. 22 In addition, SIRT1 is involved in the regulation of higher-order chromatin structure. 26 Am J Hematol. Island, NY).
The human SIRT1 knockdown vector pSUPER.retro.puro-shSIRT1
was acquired and generated as previously described. 28 The human SIRT1 expression vector pBABE.puro-SIRT1 was generated by subcloning SIRT1 cDNA from pcDNA3.1-SIRT1 28 into a pBABE retroviral vector through BamHI and BstxI restriction sites. Antibodies to SIRT1 and g-globin were purchased from Santa Cruz Biotechnology (Dallas, Texas). Antibody to b-actin was purchased from Sigma-Aldrich (Sigma A, St. Louis, MO).
| Erythroid progenitor cultures and treatment with SIRT1 activators
De-identified peripheral blood samples from adults and cord blood were purchased from Research Blood Components, LLC (Boston, MA 02135) and New York Blood Center, Inc. (New York, NY 10065). Erythroid progenitors were cultured in a two-phase system, as previously described. [29] [30] [31] Briefly, mononuclear cells from adult peripheral blood (PBMC) or cold blood were isolated on Ficoll-Paque (GE Healthcare, Piscataway, NJ), and cultured in a two-phase culture system. 29 The first phase media utilized HyClone TM IMDM (Thermo Scientific, Waltham, MA) containing 30% charcoal treated fetal bovine serum (Life Technology, New York, NY) and rHuIL-3 (25 ng/mL), rHuSCF (50 ng/mL), and rHuEPO at (0.1 u/mL) (GenScript, Piscataway, NJ) for the first 7 days, followed by replacement second phase differentiation media, with 30% charcoal treated fetal bovine serum, rHuEPO at 3 U/mL, and rHuIL-3 
| Stable knockdown of SIRT1 in K562 cells
The SIRT1 shRNA or scrambled shRNA retrovirus described above was transferred to K562 cell cultures. Infected cells were selected with puromycin for 2 weeks, and the stably infected colonies were pooled for further analysis.
| Ectopic expression of SIRT1 in erythroid progenitor cells
Erythroid progenitors from cord blood were used in this study. At day 1 of phase 2 culture, the cells were infected with retroviruses that contained either pBABE-SIRT1 or empty pBABE-vector control. At day 3, the cells were cultured in the presence of puromycin. The cells were collected at day 12 of phase 2 for mRNA analysis and at day 14 for g-globin protein analysis by immunoblotting. 
| Immunoblotting
Cells were lysed in Laemmli sample buffer and subjected to SDS-PAGE, as previously described. 29 Proteins were transferred to a nitrocellulose membrane and probed with antibodies to human g-globin, 
| Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were performed as described previously, using 2 3 10 6 cells for each assay. 
| Chromatin conformation capture analysis
Chromatin conformation capture (3C) analysis was performed as previously described using EcoRI cleavage. 33, 34 Briefly, stable SIRT1 knockdown and shRNA control K562 cells (2 x 10 6 ) were cross-linked with 1% formaldehyde (Sigma) at room temperature for 10 min, followed by glycine quenching, cell lysis and nucleus isolation. SIRT1 mRNA levels were elevated 2.9-fold ( Figure 1F ), HBG mRNA levels increased 4-fold ( Figure 1G ). The g-globin protein level increased 2.5-fold from SIRT1 ectopic expression ( Figure 1H ). Together, these results suggest that SIRT1 is an activator of HBG expression and g-globin production.
| SIRT1 activators induced HBG expression in cord blood erythroid progenitor cells
To determine whether small molecule SIRT1 activators might be useful as reagents for treating b-hemoglobinopathies, SIRT1 activators SRT2104 and SRT1720 36 were incubated with erythroid progenitor cells from cord blood. SRT2104 induced HBG transcription in a dose dependent manner ( Figure 2A ): Incubation at 100 nM, 500 nM, and 2 uM concentrations induced a mean increase of 2.4-fold, 3.4-fold, and 8.1-fold in HBG mRNA, respectively, compared with vehicle treated controls (P < .01). Treatment with hydroxyurea at 50 uM increased HBG mRNA 1.9-fold (P < .05) (Figure 2A ). SRT1720 at 500 nM and 5 uM concentrations induced a mean increase of 2.1-fold and 4.4-fold in HBG mRNA levels above the controls, respectively (P < .05) ( Figure 2B ).
Immunoblotting showed significant increases in g-globin levels in cultures treated with SRT2104 and SRT1720 ( Figure 2C ).
Using immunofluorescence staining and flow cytometry, we further determined the effect of SIRT1 activation on the change of number of HbF expressing cells (F-cells) in proportion to the erythroid progenitor cell population. All SRT2104-treated cultures contained a higher percentage of F-cells ( Figure 2D ,E). SRT2104 treatment at 100 nM, 500 nM, and 2 uM induced a mean absolute F-cell increase of 7.1%, 9.6% and 11.6% respectively (P < .01); hydroxyurea at 50 uM induced a 4.7% increase compared with controls from the same subject (P < .05) ( Figure 2D ,E).
Small molecule SIRT1 activators increased SIRT1 deacetylase activity rather than change SIRT1 mRNA or protein levels. 36 We therefore further examined whether SRT2104 or SRT1720 regulated HBG expression through targeting SIRT1 deacetylase activity. It is well established that lysine 382 in p53 is a cellular substrate of SIRT1. 37 We therefore assessed the levels of lysine 382-acetylated p53 in erythroid progenitor cells exposed to SRT2104 and SRT1720 in comparison with the vehicle control. Treatment with SRT2104 and SRT1720 decreased the acetylation levels of p53, a known biological substrate of SIRT1
( Figure 2F ). This finding demonstrates on-target SIRT1 activation activity of SRT2104 and SRT1720, and SIRT1 activation increased HBG expression, g-globin and F-cell production. HBG mRNA above controls ( Figure 3A ) (P < .05). SRT1720 at 2.5 uM induced a mean increase of 3.3-fold HBG mRNA above controls ( Figure   3A ). Western blot analysis showed that g-globin was increased 3-fold and 5-fold from exposure to SRT1720 at 2.5 uM and SRT2104 at 2 uM, respectively ( Figure 3B ). SRT2104 treatment at 500 nM and 2 uM induced a mean absolute increase of 2.7% (P < .05) and 6.5% in F-cells (P < .01), compared with controls from the same subjects ( Figure 3C,D) .
This suggested that small molecule SIRT1 activators can reactivate silenced HBG expression, g-globin and F-cell production.
| SIRT1 protein level is downregulated in adult compared with cord blood erythroid progenitor cells
While it is known that HBG is silenced in adult cells or decreased after erythroid progenitor cell differentiation, we sought to determine whether the level of SIRT1 was positively associated with the level of g-globin chains. We performed an immunoblotting assay to compare SIRT1 levels in cord blood and adult erythroid progenitor cells and in undifferentiated and differentiated erythroid progenitor cells from cord blood. SIRT1 levels were decreased 6.5-fold in adult compared with cord blood progenitor cells (Supporting Information Figure S1A ,B), and SIRT1 levels were decreased 5-fold when erythroid progenitor cells from cord blood were differentiated 12 days (Supporting Information Figure S1C ). This result is consistent with the finding that SIRT1 levels are much higher in fetal than adult liver in both human 38, 39 and mouse, 40, 41 which suggested that SIRT1 downregulation in adults may play a physiological role in HBG silencing. 
| Effects of SIRT1 on cell proliferation and differentiation
Increased proliferation or delayed differentiation of erythroid progenitor cells can contribute to elevated HbF. 42 As SIRT1 has been shown to be involved in cell growth and apoptosis we explored the mechanism by which SIRT1 regulates HBG expression by first determining whether SIRT1 played a role in erythroid progenitor cell proliferation. 19 Cell numbers were counted in either the absence or presence of SIRT1 activators. As shown in Supporting Information Figure S1D , the cells exhibited comparable proliferation rates in control and SRT2104 treated cultures at 100 nM and 500 nM (Supporting Information Figure S1D ).
Cells treated with SRT2104 at 2 uM and 5 uM also trended toward increased proliferation, but differences were not significant (p 5 0.07 at 2 uM and p 5 0.19 at 5 uM) (Supporting Information Figure S1D ).
SRT2104 treatment at 10 uM, however, significantly reduced cell proliferation (P < .05) (Supporting Information Figure S1D ). Given that SIRT1 activators were administered at concentrations that elevate HBG level (SRT2104 at 500 nM and 2 uM) (Figures 2 and 3 ) and did not affect cell proliferation, our results suggested that SIRT1 did not regulate HBG expression via an effect on cell proliferation.
We next determined whether the g-globin induction by SIRT1 could be the result of a shift in erythroid progenitor and erythroblast differentiation and maturation. Glycophorin A (CD235a) is an established lineage specific marker for erythroid maturation and differentiation, and with erythroid progenitor differentiation, CD235a levels are increased.
Erythroid progenitors from cord blood were differentiated with and without the SIRT1 activator SRT2104, and the resulting differentiated cells at day 7 and day 14 were examined by flow cytometry using marker CD235a. 43 SRT2104 treatment did not change the cell populations expressing CD235a, compared with controls (Supporting Information Figure S1E ). This suggested that SIRT1-mediated HBG upregulation most likely is not due to a change in erythroid progenitor cell differentiation or a shift in the erythroid progenitor and erythroblast cell populations.
3.6 | SIRT1 binds in the LCR and to the HBG promoter, and facilitated LCR looping SIRT1 can bind to multiple gene promoters or enhancers to regulate transcription by directly deacetylating histones, or interacting with and deacetylating transcription factors or co-regulators. 21, 22 To further understand the mechanism of SIRT1 activation of HBG transcription, we used ChIP to study SIRT1 binding to the LCR and HBG promoter in stable SIRT1 knockdown and shRNA control K562 cells. Specific SIRT1 binding in the LCR and HBG promoter was detected while no signal was found in the control sequences ( Figure 4A ). SIRT1 binding was greater in the LCR than in the HBG promoter; there was a 3.8-fold We, next performed chromatin conformation capture (3C) analysis to study whether SIRT1 regulated LCR and HBG interaction (LCR looping), using stable SIRT1 knockdown and shRNA control K562 cells.
SIRT1 knockdown resulted in a 3-fold (P < .05) decrease in the interaction of the LCR and HBG promoter ( Figure 4C ). SIRT1 did not appear to play a role in the interaction of the LCR with the HBD promoter (Figure 4C) . These results suggested that SIRT1-mediated LCR looping to HBG promoter might be one of the mechanisms by which SIRT1 regulates HBG expression. 3.7 | SIRT1 selectively regulated HBG co-suppressor gene expression
As SIRT1 can regulate transcription of many genes, we also determined whether SIRT1 might play a role in controlling expression of HBG corepressors. We used qRT-PCR analyses to determine the effect of SIRT1 activator treatment on the expression of the established HBG suppressors BCL11A, ZBTB7A, KLF1, LSD1, HDAC1, HDAC2, and HDAC3. BCL11A, KLF1, HDAC1, and HDAC2 mRNA levels were significantly down-regulated by SRT2104 ( Figure 4D ), whereas levels of ZBTB7A, LSD1 and HDAC3 transcripts were unaffected (data not shown). SRT2104 treatment at 2 uM decreased BCL11A 3.5-fold (P < .01), KLF1 3-fold (P < .05), HDAC1 2-fold (P < .05), and HDAC2 3-fold (P < .01), respectively ( Figure 4D ). These data suggested that inhibiting HBG suppressors could be another mechanism by which SIRT1 activated HBG gene expression through transcription reprogramming mechanism. Figure S1D ), suggesting that this is not a mechanism by which SIRT1 effects HBG expression. SIRT1 did not change the expression of CD235a (Supporting Information Figure S1E ), suggesting that erythroid differentiation was not an element of SIRT1-mediated HBG expression in vitro. This data is consistent with the finding that SIRT1 deletion in adult mice had no effect on the production of mature blood cells and hematopoiesis. [44] [45] [46] However, there is a report showing that SIRT1 knockout affects primitive but not definitive hematopoiesis. 47 Whether SIRT1 regulates differentiation in different cell culture system and in vivo needs further study.
| D I SCUSSION
SIRT1 can deacetylate both nonhistone and histone proteins. 19, 21 Deacetylation of histones in gene promoters suppresses transcription. 48 ChIP experiments showed that SIRT1 knockdown caused a decreased H4K16Ac level in the HBG promoter ( Figure 4B ) but had no effect on acetylated H3K9. This suggested that SIRT1 did not directly deacetylate histone in the HBG promoter, but rather indirectly regulated histone acetylation, perhaps by inhibiting HDAC1 and HDAC2
( Figure 4D ). SIRT1 binds directly to the LCR and HBG promoter and favors LCR looping, suggesting that SIRT1 might also interact with and deacetylate transcription factors or co-regulators altering transcription complex formation to activate HBG transcription. BCL11A is a key transcription factors regulating LCR looping and HBG silencing. 33, [49] [50] [51] A direct interaction between SIRT1 and BCL11A has been previously reported. 52 Whether SIRT1 and BCL11A form complexes involved in the interaction of the LCR with globin-gene promoters is under study.
Our data showed that SIRT1 inhibited the expression of HBG repressors, including BLC11A, KLF1, HDAC1, and HDAC2. These data support the role of SIRT1 as an activator of HBG transcription through a transcription reprogramming mechanism.
Other mechanisms by which SIRT1 regulates HBG transcription are possible. For example, SIRT1 deacetylates and increases the transcription function of FOXO3a, which has been shown to regulate HBG transcription. 53 SIRT1 was also involved in the stress response 54 that upregulates HBG expression. 55 In addition, more extensive studies in 
